Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in peritubular myoid cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10499
Sealed predictions
- CBLN4 in dopamine neurons, braak+0.13 (p 0.732) → +0.85 (p 0.004)receipt 10506
Swarm cases
receipt 10506: CBLN4 in dopamine neurons, braak
- power
- full sample +0.48 (p 0.046, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.45 (p 0.063, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.41 (p 0.087, n 18). could be the mix.
- skeptic
- leave-one-out range +0.41 to +0.63, sign flips 0; without severely affected donors +0.48 (p 0.046, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CBLN4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts